Zacks Investment Research initiated coverage on Tiziana Life Sciences with a new price target

4/12/21 11:57:17 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Zacks Investment Research initiated coverage of Tiziana Life Sciences with a rating of Not Rated and set a new price target of $7.50

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TLSA

Date	Price Target	Rating	Analyst